Phase 3 HAE Clinical Trials
58 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 58 trials
Recruiting
Phase 3
Donidalorsen Treatment in Children With Hereditary Angioedema
Hereditary Angioedema (HAE)
Ionis Pharmaceuticals, Inc.20 enrolled8 locationsNCT07298447
Recruiting
Phase 3
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Hereditary AngioedemaHereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled51 locationsNCT06960213
Recruiting
Phase 3
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Hereditary Angioedema (HAE)
Pharvaris Netherlands B.V.170 enrolled62 locationsNCT06679881
Recruiting
Phase 3
A Study of Navenibart in Participants With Hereditary Angioedema
Hereditary Angioedema (HAE)
Astria Therapeutics, Inc.145 enrolled87 locationsNCT06842823
Recruiting
Phase 3
A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Autoimmune Haemolytic Anaemia
Sanofi90 enrolled92 locationsNCT07086976
Recruiting
Phase 3
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled48 locationsNCT07428499
Recruiting
Phase 3
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
Haemophilia A (Moderate or Severe)
Swedish Orphan Biovitrum104 enrolled24 locationsNCT06716814
Recruiting
Phase 3
Avoiding Anticoagulation After IntraCerebral Haemorrhage
Atrial FibrillationIntracerebral HemorrhageMicrohaemorrhage
University Hospital, Lille300 enrolled3 locationsNCT03243175
Recruiting
Phase 3
EVE TRIAL , ALMA SYSTAM
Postpartum Haemorrhage (PPH)PPHPostpartum Hemorrhage (Primary)
ResQ Medical Ltd50 enrolled2 locationsNCT06646653
Recruiting
Phase 3
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Myasthaenia Gravis
Cartesian Therapeutics100 enrolled34 locationsNCT06799247
Recruiting
Phase 2Phase 3
Minocycline in Stroke Study at Maimonides
Cerebrovascular Accident (Stroke)StrokeMortality+4 more
Joyce Chen1,164 enrolled1 locationNCT07237048
Recruiting
Phase 3
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
Haemophilia A
Sinocelltech Ltd.36 enrolled1 locationNCT07437404
Recruiting
Phase 3
Fibrinogen Early In Severe Trauma StudY II
coagulopathyTraumaHaemorrhagic Shock
Australian and New Zealand Intensive Care Research Centre900 enrolled24 locationsNCT05449834
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 3
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
TJ Biopharma Co., Ltd.30 enrolled15 locationsNCT07208058
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
MalignancyGastric CancerSoft Tissue Sarcoma+8 more
Cancer Research UK30 enrolled17 locationsNCT06988475
Recruiting
Phase 2Phase 3
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Haematological MalignancySolid Tumour
Cancer Research UK825 enrolled27 locationsNCT05722886
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
MalignancyMelanomaCancer+8 more
Cancer Research UK30 enrolled27 locationsNCT05770544
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
MelanomaCarcinoma, Non-Small Cell LungOvarian Neoplasms+9 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037